There are 2789 resources available
867P - A phase I trial of nab-paclitaxel-based induction followed by nab-paclitaxel-based concurrent chemotherapy and re-irradiation in previously treated head and neck squamous cell carcinoma
Presenter: Ari Rosenberg
Session: ePoster Display
869P - Nivolumab (Nivo) and ipilimumab (Ipi) combined with radiotherapy (RT) in patients (pts) with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN): Updated results of a pilot study
Presenter: Jennifer Johnson
Session: ePoster Display
919P - Survival impact of nutritional status of locally advanced head and neck cancer squamous cell carcinoma (HNSCC) patients treated with chemoradiotherapy: A prospective observational study
Presenter: Ratchadakorn Meesart
Session: ePoster Display
920P - The sarcopenia skeletal muscle mass index (SMI) has a three-tier survival effect in HNSCC, which can be predicted by hemoglobin (Hb), lymphocytes (Ly) and creatinine (Cre)
Presenter: Simona Guerriero
Session: ePoster Display
921P - Assessment of health-related quality of life in head and neck cancer patients treated with chemoradiation
Presenter: VINAYAKUMAR MUTTAGI
Session: ePoster Display
922P - Efficacy of immunotherapy (IO) and subsequent systemic treatment after failure of IO in patients with recurrent or metastatic head and neck cancer in a real-world setting
Presenter: Michael Pogorzelski
Session: ePoster Display
923P - Nivolumab in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck (R/M SCCHN) progressing on/or after a platinum-based therapy: Interim analysis of a prospective French real-world study (ProNiHN)
Presenter: Christophe Le Tourneau
Session: ePoster Display